GMAB
Price
$24.52
Change
+$0.21 (+0.86%)
Updated
Aug 26, 04:59 PM (EDT)
Capitalization
15.19B
72 days until earnings call
TECH
Price
$56.79
Change
+$0.08 (+0.14%)
Updated
Aug 26 closing price
Capitalization
8.83B
69 days until earnings call
Interact to see
Advertisement

GMAB vs TECH

Header iconGMAB vs TECH Comparison
Open Charts GMAB vs TECHBanner chart's image
Genmab A/S ADS
Price$24.52
Change+$0.21 (+0.86%)
Volume$9.78K
Capitalization15.19B
Bio-Techne
Price$56.79
Change+$0.08 (+0.14%)
Volume$1.87M
Capitalization8.83B
GMAB vs TECH Comparison Chart in %
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. TECH commentary
Aug 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Buy and TECH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 27, 2025
Stock price -- (GMAB: $24.31 vs. TECH: $56.79)
Brand notoriety: GMAB and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 93% vs. TECH: 89%
Market capitalization -- GMAB: $15.19B vs. TECH: $8.83B
GMAB [@Biotechnology] is valued at $15.19B. TECH’s [@Biotechnology] market capitalization is $8.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, both GMAB and TECH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 6 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • GMAB’s TA Score: 6 bullish, 4 bearish.
  • TECH’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both GMAB and TECH are a good buy in the short-term.

Price Growth

GMAB (@Biotechnology) experienced а +3.80% price change this week, while TECH (@Biotechnology) price change was +3.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.74%. For the same industry, the average monthly price growth was +18.58%, and the average quarterly price growth was +32.83%.

Reported Earning Dates

GMAB is expected to report earnings on Nov 06, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+4.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($15.2B) has a higher market cap than TECH($8.83B). TECH has higher P/E ratio than GMAB: TECH (123.46) vs GMAB (12.69). GMAB YTD gains are higher at: 16.483 vs. TECH (-20.816). GMAB has higher annual earnings (EBITDA): 1.48B vs. TECH (283M). GMAB has less debt than TECH: GMAB (148M) vs TECH (423M). GMAB has higher revenues than TECH: GMAB (3.26B) vs TECH (1.21B).
GMABTECHGMAB / TECH
Capitalization15.2B8.83B172%
EBITDA1.48B283M522%
Gain YTD16.483-20.816-79%
P/E Ratio12.69123.4610%
Revenue3.26B1.21B270%
Total Cash2.9BN/A-
Total Debt148M423M35%
FUNDAMENTALS RATINGS
GMAB vs TECH: Fundamental Ratings
GMAB
TECH
OUTLOOK RATING
1..100
1754
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3780
PRICE GROWTH RATING
1..100
4954
P/E GROWTH RATING
1..100
9211
SEASONALITY SCORE
1..100
1175

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for GMAB (61) in the null industry. This means that TECH’s stock grew somewhat faster than GMAB’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that TECH’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (37) in the null industry is somewhat better than the same rating for TECH (80) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than TECH’s over the last 12 months.

GMAB's Price Growth Rating (49) in the null industry is in the same range as TECH (54) in the Biotechnology industry. This means that GMAB’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for GMAB (92) in the null industry. This means that TECH’s stock grew significantly faster than GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABTECH
RSI
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 5 days ago
63%
Bullish Trend 14 days ago
72%
Declines
ODDS (%)
Bearish Trend 16 days ago
69%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMRPX10.280.05
+0.49%
Westwood Salient MLP & Engy Infras Ultr
VIMAX357.43N/A
N/A
Vanguard Mid Cap Index Admiral
HEORX18.09N/A
N/A
Hartford Climate Opportunities R3
FIDJX14.92N/A
N/A
Fidelity SAI Sustainable Sector Fund
TGVRX31.21-0.20
-0.64%
Thornburg International Equity R3

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.38%
GNMSF - GMAB
58%
Loosely correlated
+0.27%
AXON - GMAB
47%
Loosely correlated
-0.35%
TECH - GMAB
40%
Loosely correlated
-0.67%
ARVN - GMAB
38%
Loosely correlated
+2.19%
IPSC - GMAB
37%
Loosely correlated
-5.54%
More